EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular mechanisms of anthracycline induced cardiotoxicity: Zebrafish come into play

Maryam Moossavi, Xiaoguang Lu, Joerg Herrmann, Xiaolei Xu

Frontiers in Cardiovascular Medicine · 10.03.2023 · 10

DOI: 10.3389/fcvm.2023.1080299 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 10.03.2023. Verfasst von Maryam Moossavi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, United States. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH, Mayo Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anthracyclines are among the most potent chemotherapeutics; however, cardiotoxicity significantly restricts their use. Indeed, anthracycline-induced cardiotoxicity (AIC) fares among the worst types of cardiomyopathy, and may only slowly and partially respond to standard heart failure therapies including β-blockers and ACE inhibitors. No therapy specifically designed to treat anthracycline cardiomyopathy at present, and neither is it known if any such strategy could be developed. To address this gap and to elucidate the molecular basis of AIC with a therapeutic goal in mind, zebrafish has been introduced as an in vivo vertebrate model about a decade ago. Here, we first review our current understanding of the basic molecular and biochemical mechanisms of AIC, and then the contribution of zebrafish to the AIC field. We summarize the generation of embryonic zebrafish AIC models (eAIC) and their use for chemical screening and assessment of genetic modifiers, and then the generation of adult zebrafish AIC models (aAIC) and their use for discovering genetic modifiers via forward mutagenesis screening, deciphering spatial-temporal-specific mechanisms of modifier genes, and prioritizing therapeutic compounds via chemical genetic tools. Several therapeutic target genes and related therapies have emerged, including a retinoic acid (RA)-based therapy for the early phase of AIC and an autophagy-based therapy that, for the first time, is able to reverse cardiac dysfunction in the late phase of AIC. We conclude that zebrafish is becoming an important in vivo model that would accelerate both mechanistic studies and therapeutic development of AIC.

Schlagwörter

Stichwörter der Autor:innen

anthracyclinesapoptosiscardiotoxicitymitochondriazebrafish

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, United States.
  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
  • School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.

Förderung

  • NHLBI NIH HHS
  • NIH
  • Mayo Foundation

Zitieren

APA

Moossavi, M., Lu, X., Herrmann, J., & Xu, X. (2023). Molecular mechanisms of anthracycline induced cardiotoxicity: Zebrafish come into play. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1080299

Vancouver

Moossavi M, Lu X, Herrmann J, Xu X. Molecular mechanisms of anthracycline induced cardiotoxicity: Zebrafish come into play. Frontiers in Cardiovascular Medicine. 2023;10. doi:10.3389/fcvm.2023.1080299

BibTeX
@article{Moossavi2023,
  author = {Moossavi, Maryam and Lu, Xiaoguang and Herrmann, Joerg and Xu, Xiaolei},
  title = {Molecular mechanisms of anthracycline induced cardiotoxicity: Zebrafish come into play},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2023},
  volume = {10},
  doi = {10.3389/fcvm.2023.1080299}
}
Kostenlos starten →